Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care

BACKGROUND: Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients. STUDY QUESTION: What is the effectiveness of rivaroxaban versus the standard of care (S...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Health Econ Outcomes Res
Main Authors: Peacock, W. Frank, Coleman, Craig I., Wells, Phil, Fermann, Gregory J., Wang, Li, Baser, Onur, Schein, Jeff, Crivera, Concetta
Formato: Artigo
Idioma:Inglês
Publicado em: Columbia Data Analytics, LLC 2019
Assuntos:
Cardiovascular Conditions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7299482/
https://ncbi.nlm.nih.gov/pubmed/32685588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.36469/9936
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados